B1 -- FIG. 1A to 1I shows the nucleotide sequence (top sequence) and the deduced amino acid sequence (bottom sequence) of the full length *98 kDa putative outer membrane protein* gene (SEQ ID NO: 1) and the processed sequence from *Chlamydia pneumoniae* (SEQ ID NO: 2). --

Please replace the paragraph beginning at line 9, pg. 8 with the following:

B2 -- FIG. 2A to 2H shows the restriction enzyme analysis of nucleotide sequence encoding the *C. pneumoniae 98 kDa putative outer membrane protein* gene. --

Please replace the paragraph beginning at line 13, pg. 16 with the following:

B3 -- A recombinant expression system can be selected from prokaryotic and eukaryotic hosts. Eukaryotic hosts include yeast cells (*e.g.*, *Saccharomyces cerevisiae* or *Pichia pastoris*), mammalian cells (*e.g.*, COS1, NIH3T3, or JEG3 cells), arthropods cells (*e.g.*, *Spodoptera frugiperda* (SF9) cells), and plant cells. Preferably, a prokaryotic host such as *E. coli* is used. Bacterial and eukaryotic cells are available from a number of different sources to those skilled in the art, *e.g.*, the American Type Culture Collection (ATCC; 10801 University Boulevard, Manassas, VA 20110-2209). --

In the claims:

Please cancel claim 17 and amend the remaining claims as follows:

B4 Sub Cancel 3. (Amended) The polynucleotide of claim 2 wherein the fusion polypeptide is a heterologous signal peptide.

4. (Amended) The polynucleotide of claim 2 wherein the polynucleotide encodes a functional fragment of the polypeptide having the SEQ ID NO: 2.

B5 Sub Cancel ~~18. (Amended) The host cell of claim 12, wherein said host cell is a prokaryotic cell.~~

B6 Sub Cancel ~~19.~~ (Amended) A pharmaceutical composition, comprising an immunologically effective amount of the vaccine vector of ~~claim 16~~.